Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.
| Revenue (Most Recent Fiscal Year) | $24.99M |
| Net Income (Most Recent Fiscal Year) | $-117.12M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -59.05% |
| Return on Assets (Trailing 12 Months) | -50.66% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.30 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 82.71M |
| Free Float | 76.26M |
| Market Capitalization | $59.55M |
| Average Volume (Last 20 Days) | 0.75M |
| Beta (Past 60 Months) | 1.76 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 83.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |